# Progress Note 05 — Sick Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Yul Brynner (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML020-SYN
- Date: 2026-10-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Simon Achterberg, MD
- Calendar frame: modern shifted

- Visit type: Sick Visit
- Services: Problem-oriented office visit, established patient

## Chief complaint

Itchy rash on the chest, back, and arms for four days, during pembrolizumab treatment. **S**

## History of present illness

Mr. Brynner is a 63-year-old man with stage IVB adenocarcinoma of the left upper lobe (PD-L1 70 percent, no actionable alteration) who had his second pembrolizumab infusion one week ago and his first zoledronic acid dose the same day. He asked for a same-day visit for an itchy rash. Four days ago he noticed small red bumps on his chest that have spread to his upper back and the inner arms. The itching is worst at night and in the heat of the stage lights at rehearsal, but he is sleeping. He has had no blisters, peeling, mouth or eye soreness, genital sores, or fever. The aches he had for a day after the zoledronic acid dose have gone. He has started no new soap, detergent, or medicine other than the infusions. He has had no diarrhea, abdominal pain, cough, breathlessness, headache, unusual fatigue, or yellowing of the skin or eyes. His voice remains improved since the injection two weeks ago. **S**

| Element | Detail |
|---|---|
| Onset | Four days ago, three and a half weeks after the first pembrolizumab dose and three days after the second |
| Location | Chest, upper back, and inner arms; face, palms, soles, and mucous membranes spared |
| Duration | Four days, slowly spreading |
| Character | Small red raised spots that join in places; itchy |
| Severity | Mild; about 8 percent of body surface area; sleeping and working |
| Timing | Itching worst at night and under hot stage lights |
| Context | On pembrolizumab every 3 weeks; first zoledronic acid dose one week ago; no new exposures |
| Modifying factors | Cool showers help; nothing taken |
| Associated signs and symptoms | Denies fever, blisters, mucosal sores, diarrhea, cough, breathlessness, headache, and jaundice |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, chills, or unusual fatigue |
| Integumentary | Positive | Itchy red rash on the trunk and arms; no blisters or peeling |
| Eyes | Negative | No redness, pain, or change in vision |
| Ears, nose, mouth, and throat | Negative | No mouth sores; voice improved |
| Respiratory | Negative | No new cough or breathlessness |
| Gastrointestinal | Negative | No diarrhea, abdominal pain, or dark urine |
| Endocrine | Negative | No headache, dizziness, heat or cold intolerance, or excessive thirst |

7 systems reviewed. **S**

## Current medications

- Pembrolizumab 200 mg intravenous infusion over 30 minutes every 3 weeks **S**
- Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every 12 weeks, for bone metastases **S**
- Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet daily, with calcium from food, while on zoledronic acid **S**
- Triamcinolone acetonide 0.1% cream, thin layer to the rash twice daily for two weeks (not on the face or skin folds) **S**
- Cetirizine 10 mg oral tablet, one tablet daily as needed for itching **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/78 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 72 kg; BMI 22.7 kg/m². All vital signs are synthetic.

TSH: 2.6 mIU/L; Free T4: 1.1 ng/dL; ALT: 28 U/L; AST: 25 U/L; Total bilirubin: 0.6 mg/dL; Creatinine: 0.9 mg/dL; Eosinophils: 0.62 10*3/uL (high). All results are synthetic.

## Change since baseline

- ALT: 24 U/L at baseline, 28 U/L at this visit **S**
- AST: 22 U/L at baseline, 25 U/L at this visit **S**
- Total bilirubin: 0.6 mg/dL at baseline, 0.6 mg/dL at this visit **S**
- Creatinine: 0.9 mg/dL at baseline, 0.9 mg/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well and comfortable; afebrile at 36.7 °C |
| Skin | Discrete and partly joined pink macules and papules over the anterior chest, upper back, and inner upper arms, about 8 percent of body surface area; scratch marks; no blisters, target lesions, skin pain, or peeling; Nikolsky sign negative |
| Mucous membranes | Mouth, lips, and eyes normal |
| Lymph nodes | No new enlargement |
| Lungs | Clear; oxygen saturation 97 percent |
| Abdomen | Soft and non-tender; no liver enlargement |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Immune-related maculopapular rash, grade 1** (L27.0). Itchy maculopapular rash over less than 10 percent of the body surface, starting three and a half weeks into pembrolizumab, without blisters, mucosal involvement, skin pain, or fever: grade 1 immune-related dermatitis. No feature of a severe cutaneous reaction. TSH 2.6, free T4 1.1, and liver tests and creatinine normal, so no second immune-related event; eosinophils mildly raised at 0.62, typical of a drug-related rash. Zoledronic acid is an unlikely cause. Pembrolizumab can continue. **S**
   - Triamcinolone 0.1% cream twice daily for up to two weeks, not on the face or skin folds.
   - Cetirizine 10 mg daily as needed for itching; fragrance-free emollient twice daily; cool showers.
   - Continue pembrolizumab on schedule; oncology informed today and agrees.
   - Return the same day for blisters, skin pain or peeling, mouth or eye sores, fever, or spread to more than a tenth of the body; photograph the rash every two days.
2. **Stage IVB adenocarcinoma of the lung on pembrolizumab** (C34.12). Second cycle given one week ago; no other immune-related symptoms. **S**
   - Cycle 3 in two weeks after the laboratory panel.
   - Response CT about nine weeks after starting, as planned.

## Medication changes

- Started: Triamcinolone acetonide 0.1% cream, thin layer to the rash twice daily for two weeks (not on the face or skin folds) **S**
- Started: Cetirizine 10 mg oral tablet, one tablet daily as needed for itching **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026), Aether Forge
- NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026), National Comprehensive Cancer Network
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021), American Society of Clinical Oncology (Schneider BJ et al., J Clin Oncol 2021;39(36):4073-4126)

## Follow-up

- Skin check at the preventive visit next week, or sooner as above. Cycle 3 in two weeks. **S**
- Next scheduled visit 2026-10-27: periodic adult preventive visit. **S**
